Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v4-FR | Version v2-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2022-08-19 | 2022-05-15 |
| Drug Identification Number | 02139561 | 02139561 |
| Brand name | OXYTOCIN INJECTION, USP | OXYTOCIN INJECTION, USP |
| Common or Proper name | Oxytocin Injection, USP Synthetic 10 USP units/mL SD Vial 1 mL | Oxytocin Injection, USP Synthetic 10 USP units/mL SD Vial 1 mL |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | OXYTOCIN | OXYTOCIN |
| Strength(s) | 10UNIT | 10UNIT |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 1mL | 1mL |
| ATC code | H01BB | H01BB |
| ATC description | POSTERIOR PITUITARY LOBE HORMONES | POSTERIOR PITUITARY LOBE HORMONES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2022-05-01 | 2022-05-01 |
| Estimated end date | 2023-01-02 | Unknown |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi would like to advise that our 100% allocation will be maintained until Sept 30, 2022. Effective Oct. 1, 2022, allocations will be reduced to 50%. Effective Nov. 1, 2022 until Jan. 2, 2023, we will be facing a supply interruption. | On 100% allocation |
| Health Canada comments |